XOMA Corp Files 8-K Report

TL;DR

XOMA filed an 8-K, looks like standard corporate housekeeping.

AI Summary

On May 30, 2024, XOMA Corporation filed an 8-K report detailing "Other Events." The filing does not contain specific financial transactions or material agreements, but rather administrative and informational updates related to the company's corporate structure and reporting.

Why It Matters

This filing indicates routine corporate activity and updates for XOMA Corporation, providing transparency to investors about the company's ongoing operations and compliance.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or significant financial events.

Key Players & Entities

• XOMA Corporation (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• May 30, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.0075 — nge on which registered: Common Stock, $0.0075 par value XOMA The Nasdaq Global Ma
• $0.05 — ve Perpetual Preferred Stock, par value $0.05 per share XOMAP The Nasdaq Global M
• $108 million — priority review voucher (the "PRV") for $108 million. The PRV was awarded to Day One followi
• $8,100,000 — any is entitled to receive from Viracta $8,100,000, representing a portion of the PRV sale

Filing Documents

• d839143d8k.htm (8-K) — 24KB
• 0001193125-24-150435.txt ( ) — 185KB
• xoma-20240530.xsd (EX-101.SCH) — 4KB
• xoma-20240530_def.xml (EX-101.DEF) — 14KB
• xoma-20240530_lab.xml (EX-101.LAB) — 23KB
• xoma-20240530_pre.xml (EX-101.PRE) — 15KB
• d839143d8k_htm.xml (XML) — 7KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 30, 2024 XOMA CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-39801 52-2154066 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 2200 Powell Street , Suite 310 , Emeryville , California 94608 (Address of Principal Executive Offices) (Zip Code) (510) 204-7200 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class: Trading symbol(s): Name of each exchange on which registered: Common Stock, $0.0075 par value XOMA The Nasdaq Global Market 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share XOMAP The Nasdaq Global Market Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share) XOMAO The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item8.01 Other Events. On May 30, 2024, Day One Biopharmaceuticals announced the sale of a priority review voucher (the "PRV") for $108 million. The PRV was awarded to Day One following approval by the U.S. Food and Drug Administration of OJEMDA (tovorafenib). As previously disclosed, in March 2021, XOMA Corporation (the "Company") acquired from Viracta Therapeutics the right to receive potential milestones and mid-single digit royalties associated with tovorafenib, plus a share of potential event-based economics. Pursuant to this agreement, the Company is entitled to receive from Viracta $8,100,000, representing a portion of the PRV sale proceeds payable by Day One to Viracta. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XOMA CORPORATION Date: May 30, 2024 By: /s/ THOMAS BURNS Thomas Burns Senior Vice President, Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR